Papers Trials Topics Compounds Countries Stakeholders People Courses Events

Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depression Drug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · Safety An international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · Neuroimaging Esketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence 02Approval 03Reimbursement 04Delivery 05Access —Big Picture

Start the journey

Enterprise IntelligenceQuarterly drug-development signals, programme moves, and catalysts.ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.

Industry News

Regulatory shifts, biotech developments, and the latest media coverage shaping the psychedelic landscape.

The intelligence layer for psychedelic research.

Company

About
Contact
Newsletter

Product

Feedback
Roadmap
Changelog
API
Partners
Clinical Guidelines

Legal

Privacy
Terms

© 2026 Blossom. All rights reserved.